Research group on Metabolic Diseases
Metabolism and Organic Damage Area
The main objective of the group is the identification of new biomarkers and therapeutic targets to restrain the main pathologies associated with metabolic dysfunction caused by diabetes and dyslipidemia. The two most important pathological consequences in severity and prevalence of the metabolic dysfunction are atherosclerotic cardiovascular disease and metabolic associated fatty liver disease (MAFLD). Tissue inflammation is one of the key mechanisms of these pathologies, so the lines of research focus on the study of the effect of inflammatory mediators, specifically the family of lymphotoxins and their receptors, on their development. To this end, experimental approaches of gain and loss of function of these mediators are used in animal models of disease and human cell cultures to evaluate their impact on key cellular events of diseases. The lines of research also include clinical studies in collaboration with the Endocrinology Service in subjects with cardiovascular pathology and diabetes. More recently, research also includes transcriptomic studies of both human and murine tissue samples in order to identify new determinants of the disease.
Coordinatora
STAFF
Collaborating Researchers
Nurse
Technicians
Administrative assistant
Publications
Vascular smooth muscle cell phenotype is modulated by ligands of the lymphotoxin β receptor and the tumor necrosis factor receptor. Martin-Vano S, Miralles-Abella A, Castano P, Hurtado-Genoves G, Aguilar-Ballester M, Herrero-Cervera A, Vinue A, Martinez-Hervas S, Gonzalez-Navarro H. Clinica e Investigacion en Arteriosclerosis. 2023 Jan-Feb;35(1):1-11. English, Spanish. doi: 10.1016/j.arteri.2022.05.003. PMID: 35738949
Novel therapies for cardiometabolic disease: recent findings in studies with hormone peptide-derived G protein coupled receptor agonists. Jimenez-Marti E, Hurtado-Genoves G, Aguilar-Ballester M, Martinez-Hervas S, Gonzalez-Navarro H. Nutrients. 2022 Sep 13;14(18):3775. doi: 10.3390/nu14183775. PMID: 36145148
RUNAT-BI: A Ruthenium(III) Complex as a Selective Anti-Tumor Drug Candidate against Highly Aggressive Cancer Cell Lines. Albanell-Fernandez M, Oltra S, Orts-Arroyo M, Ibarrola-Villava M, Carrasco F, Jimenez-Marti E, Cervantes A, Castro I, Martinez-Lillo J, Ribas G. Cancers. 2022 Dec 22;15(1):69. doi: 10.3390/cancers15010069. PMID: 36612065
Intra-tumour genetic heterogeneity and prognosis in high-risk neuroblastoma. Lopez-Carrasco A, Berbegall A, Martin-Vano S, Blanquer-Maceiras M, Castel V, Navarro S, Noguera R. Cancers. 2021 Oct 15;13(20):5173. doi: 10.3390/cancers13205173. PMID: 34680323
Overexpression of glucose 6 phosphate dehydrogenase preserves mouse pancreatic beta cells function until late in life. De la Rosa A, Gomez-Cabrera M, Vinue A, Gonzalez-Navarro H, Sanchez-Andres J, Vina J. Free radical biology & medicine. 2021 Feb 20;164:149-153. doi: 10.1016/j.freeradbiomed.2020.12.439. PMID: 33418115
Postprandial triglyceridemia is modulated by insulin resistance but not by grade of obesity in abdominal and morbid obese subjects. Moreno-Perez B, Benito E, Civera M, Alabadi B, Martinez-Hervas S, Peiro M, Gonzalez-Navarro H, Piqueras L, Jesus Sanz M, Ascaso J, Real J. International Journal of Clinical Practice. 2021 Apr;75(4):e13776. doi: 10.1111/ijcp.13776. PMID: 33089594
Therapies for the Treatment of Cardiovascular Disease Associated with Type 2 Diabetes and Dyslipidemia. Aguilar-Ballester M, Hurtado-Genoves G, Taberner-Cortes A, Herrero-Cervera A, Martinez-Hervas S, Gonzalez-Navarro H. International Journal Of Molecular Sciences. 2021 Jan 11;22(2):660. doi: 10.3390/ijms22020660. PMID: 33440821
Projects
Title: Identificación de nuevas dianas terapéuticas y mecanismos de la modulación de la inflamación en las enfermedades metabólicas
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Herminia González Navarro, Sergio Martínez Hervás
Duration: 2023 – 2025
Total budget: 147.620,00 €
Title: Plan GenT
Funding body: Conselleria de Sanidad
Principal Investigator: Herminia González Navarro
Duration: 2020 – 2023
Total budget: 253.000 €
Title: Papel de los procesos inflamatorios en las enfermedades metabólicas y en las complicaciones asociadas
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Herminia González Navarro, Sergio Martínez Hervás
Duration: 2020 – 2022
Total budget: 159.720 €
Title: Catalysing transcriptomics research in cardiovascular disease
Funding body: European Commission
Principal Investigator: Yvan Devaux
Duration: 2018 – 2023
Total budget: 0
Title: Papel de los procesos inflamatorios asociados a la diabetes en la estabilidad de la placa de ateroma y estudio del uso potencial de estrategias terapéuticas
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Herminia González Navarro
Duration: 2017 – 2019
Total budget: 122.815 €
+ Info
Doctoral candidate: Taberner Cortés, Aida
Director(s): González Navarro, Herminia
Date of the defense: 11/11/2021
University: Universitat Politècnica de València
Title: Papel de la citoquina light en la esteatosis hepática y la resistencia a insulina
Doctoral candidate: Herrero Cervera, Andrea
Director(s): González Navarro, Herminia
Date of the defense: 21/01/2020
University: Universitat Politècnica de València